ASAN vs NVDA

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score, limiting distress risk assessment. Despite strong gross margins and accelerating revenue and earnings growth, the company remains deeply unprofitable with negative ROE and ROA, high valuation multiples, and deteriorating insider sentiment. Aggressive insider selling, a bearish technical trend, and a significant disconnect between current price and analyst target further weigh on the outlook. While earnings surprises have been consistently positive, the overall risk profile remains elevated in a high-valuation, low-profitability context.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.